| 英文摘要 |
The purpose of this project was to increase the percentage of hemodialysis patients with a hematocrit (Hct) level of over 26% to 90% and maintain a target Hct of over 33% to alleviate anemia symptoms among patients. Unit records for January through to September, 2010, showed that only 85.5% of patients had a Hct above the accreditation threshold of 26%. Furthermore, only 35.8% patients had a Hct of over 35.8% from the main causes included intravenous injection of erythropoietin (EPO), lack of iron supplements, clotting in the dialyzer, bleeding, poor diet control and underlying disease. As a result, we used subcutaneous EPO injection, adjusted iron supplements, revised standard hemodialysis protocols, and nursing guidance. At end of this study, 40.6% patients had a Hct over 33% and 90.9% patients had a Hct above 26%. Total cost of EPO also decreased from NT$ 901,530 to NT$ 721,224. |
